Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17027212rdf:typepubmed:Citationlld:pubmed
pubmed-article:17027212lifeskim:mentionsumls-concept:C0027567lld:lifeskim
pubmed-article:17027212lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:17027212lifeskim:mentionsumls-concept:C0037791lld:lifeskim
pubmed-article:17027212pubmed:issue9lld:pubmed
pubmed-article:17027212pubmed:dateCreated2006-10-23lld:pubmed
pubmed-article:17027212pubmed:abstractTextSince the Durban conference in 2000, the initiatives of access to antiretroviral therapy (ART) have expanded in sub-Saharan Africa. It is of high interest to monitor observance to HAART, in a context of increasing ART use, a rapid increase of patients under HAART, and the sociocultural specificities in Africa. In sub-Saharan Africa the concept of disease without cure does not exist and a disease always has or is attributed an external cause. Optimizing observance is a key element for the success of implementation programs for which we recommend a light monitoring to follow-up patients and the use of first line and effective antiretroviral drugs, with a low genetic barrier (efavirenz, nevirapine). The consequences of non-adherence are extremely negative for a patient in Africa, for whom we have few assessment tools and a limited number of ART. Improvement of adherence requires the involvement of all health care actors including traditional healers.lld:pubmed
pubmed-article:17027212pubmed:languagefrelld:pubmed
pubmed-article:17027212pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17027212pubmed:citationSubsetIMlld:pubmed
pubmed-article:17027212pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17027212pubmed:statusMEDLINElld:pubmed
pubmed-article:17027212pubmed:monthSeplld:pubmed
pubmed-article:17027212pubmed:issn0399-077Xlld:pubmed
pubmed-article:17027212pubmed:authorpubmed-author:CisséMMlld:pubmed
pubmed-article:17027212pubmed:authorpubmed-author:BissagnénéEElld:pubmed
pubmed-article:17027212pubmed:authorpubmed-author:GirardP-MPMlld:pubmed
pubmed-article:17027212pubmed:authorpubmed-author:EholiéS-PSPlld:pubmed
pubmed-article:17027212pubmed:authorpubmed-author:N'dourC-TCTlld:pubmed
pubmed-article:17027212pubmed:issnTypePrintlld:pubmed
pubmed-article:17027212pubmed:volume36lld:pubmed
pubmed-article:17027212pubmed:ownerNLMlld:pubmed
pubmed-article:17027212pubmed:authorsCompleteYlld:pubmed
pubmed-article:17027212pubmed:pagination443-8lld:pubmed
pubmed-article:17027212pubmed:meshHeadingpubmed-meshheading:17027212...lld:pubmed
pubmed-article:17027212pubmed:meshHeadingpubmed-meshheading:17027212...lld:pubmed
pubmed-article:17027212pubmed:meshHeadingpubmed-meshheading:17027212...lld:pubmed
pubmed-article:17027212pubmed:meshHeadingpubmed-meshheading:17027212...lld:pubmed
pubmed-article:17027212pubmed:meshHeadingpubmed-meshheading:17027212...lld:pubmed
pubmed-article:17027212pubmed:meshHeadingpubmed-meshheading:17027212...lld:pubmed
pubmed-article:17027212pubmed:meshHeadingpubmed-meshheading:17027212...lld:pubmed
pubmed-article:17027212pubmed:year2006lld:pubmed
pubmed-article:17027212pubmed:articleTitle[Observance of antiretroviral treatments: African specificities].lld:pubmed
pubmed-article:17027212pubmed:affiliationService des Maladies Infectieuses et Tropicales, BPV 3 CHU Treichville, Abidjan, Côte d'Ivoire. speholie@globeaccess.netlld:pubmed
pubmed-article:17027212pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:17027212pubmed:publicationTypeEnglish Abstractlld:pubmed
pubmed-article:17027212pubmed:publicationTypeReviewlld:pubmed